Patient reported outcomes for the CANDOR trial for multiple myeloma
Published: 13 Jun 2020
Views: 286
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Prof Katja Weisel speaks to ecancer online at the EHA virtual conference 2020 about the CANDOR trial patient reported outcomes.
She explains how the patients reported their outcomes through a life-quality evaluation questionnaire, and explains why this feedback is so important.
Prof Weisel emphasises why this especially important in diseases like multiple myeloma because patients can live a long time with treatment, and constant feedback is important for a better quality of life.
Related Videos
COVID-19: Management of non-small cell lung cancer patients during the coronavir...
Dr Heather Wakelee - Stanford University, Stanford, USA
12 May 2020
Managing Hodgkin lymphoma during the COVID-19 outbreak
Dr Anna Sureda - Hospitalet de Llobregat, Barcelona, Spain
20 Apr 2020
Providing practical tips for completing geriatric assessments
Dr Melissa Loh - Rochester Medical Center, Rochester, USA
5 Dec 2019
New approaches and highlights from SIOG 2019
Dr Hans Wildiers - President, SIOG
29 Nov 2019
The young SIOG interest group
Dr Nicolò Battisti - The Royal Marsden NHS Foundation Trust, London, UK
29 Nov 2019
The importance of proper geriatric classification for haematological malignancie...
Dr Raúl Cordoba - Jiménez Diaz Foundation University Hospital, Madrid, Spain
29 Nov 2019
The missions and future of SIOG
Prof Hans Wildiers - University Hospitals Leuven, Leuven, Belgium
23 Nov 2018
Patient empowerment through iManageCancer
Prof Gordon McVie - ecancer, Bristol, UK
6 Aug 2018
